{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:04:05Z","timestamp":1761167045357,"version":"build-2065373602"},"reference-count":127,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.dld.2018.09.022","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T18:20:16Z","timestamp":1538418016000},"page":"10-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["AISF position paper on HCV in immunocompromised patients"],"prefix":"10.1016","volume":"51","author":[{"given":"Alfredo","family":"Marzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Astegiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Baratelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizia Rossana","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuseppina","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Chial\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Colli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"De Gasperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clodoveo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Battista","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Antonio","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Imperatrice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Salvatore","family":"Macaluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Marignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mazzarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Pasulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rendina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Toniutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Vajro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Volpes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Linda","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"Sistema Nazionale per le Linee Guida Manuale metodologico","key":"10.1016\/j.dld.2018.09.022_bib0005"},{"key":"10.1016\/j.dld.2018.09.022_bib0010","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"10.1016\/j.dld.2018.09.022_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.dld.2018.09.022_bib0020","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dld.2018.09.022_bib0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2007.06.059","article-title":"HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)","volume":"133","author":"Pilli","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0030","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/liv.13203","article-title":"Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature","volume":"36","author":"D\u2019Ambrosio","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.09.022_bib0035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.5009\/gnl16434","article-title":"Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy","volume":"11","author":"Lee","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2018.09.022_bib0045","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/annonc\/mdp458","article-title":"Effects of chronic hepatitis C infection on the treatment of breast cancer patients","volume":"21","author":"Morrow","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.09.022_bib0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/14740338.2017.1325869","article-title":"Hepatitis B reactivation during or after direct acting antiviral therapy \u2014 implication for susceptible individuals","volume":"16","author":"Holmes","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.dld.2018.09.022_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.dld.2018.09.022_bib0060","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0065","first-page":"26","article-title":"Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy","volume":"41","author":"Buonomo","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.dld.2018.09.022_bib0070","first-page":"S7","article-title":"HCV \u2014 estimation of the number of diagnosed patients eligible to the new anti-HCV therapies in Italy","volume":"20","author":"Gardini","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"July","key":"10.1016\/j.dld.2018.09.022_bib0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejim.2018.02.015","article-title":"Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population-based survey","volume":"53","author":"Andriulli","year":"2018","journal-title":"Eur J Int Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jmv.24635","article-title":"Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades","volume":"89","author":"Morisco","year":"2017","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2018.09.022_bib0085","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2009.08.004","article-title":"The long and winding road leading to the identification of the hepatitis C virus","volume":"51","author":"Houghton","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0090","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/JVI.06242-11","article-title":"Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122","volume":"86","author":"Kambara","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.dld.2018.09.022_bib0095","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0100","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.12.010","article-title":"Immune response to HCV and other hepatitis viruses","volume":"40","author":"Park","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.dld.2018.09.022_bib0110","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.dld.2018.09.022_bib0115","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.00499-17","article-title":"Hepatitis C Virus lipoviroparticles assemble in the endoplasmic reticulum (ER) and bud off from the ER to the Golgi compartment in COPII vesicles","volume":"91","author":"Syed","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.dld.2018.09.022_bib0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jare.2016.11.003","article-title":"Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: a review","volume":"8","author":"Gastaldi","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.dld.2018.09.022_bib0130","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.11427","article-title":"Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection","volume":"97","author":"Ohata","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2018.09.022_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: noninvasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0145","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.5009\/gnl16434","article-title":"Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy","volume":"11","author":"Lee","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2018.09.022_bib0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3322\/caac.21403","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2018.09.022_bib0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3350\/kjhep.2011.17.4.299","article-title":"Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization","volume":"17","author":"Sung","year":"2011","journal-title":"Korean J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2018.09.022_bib0170","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1182\/blood-2010-09-307827","article-title":"Hepatitis C in the rituximab era","volume":"116","author":"Foran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0175","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6","article-title":"Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies","volume":"83","author":"Zuckerman","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2018.09.022_bib0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in HCV infected patients with diffuse large B cell non-Hodgkin lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0185","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cgh.2017.10.032","article-title":"Treatment of acute hepatitis C with ledipasvir and sofosbuvir in patients with hematological malignancies allows early re-start of chemotherapy","volume":"16","author":"Brancaccio","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0190","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2018.09.022_bib0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","article-title":"Hepatitis C-associated B-cell non Hodgkin lymphomas. Epidemiology, molecular signature and clinical management","volume":"59","author":"Peveling-Oberhag","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0205","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","article-title":"Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment","volume":"125","author":"Sultanik","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0210","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon- free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"1128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0215","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMc1513288","article-title":"Remission of follicular lymphoma after treatment for hepatitis C virus infection","volume":"375","author":"Maciocia","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0220","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1200\/JOP.2013.001215","article-title":"Hepatitis C virus screening in patients with cancer receiving chemotherapy","volume":"10","author":"Hwang","year":"2014","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.dld.2018.09.022_bib0225","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1186\/s12885-015-2033-z","article-title":"Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors","volume":"15","author":"Brasseur","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2018.09.022_bib0230","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cgh.2013.10.034","article-title":"Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?","volume":"12","author":"Mahale","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/2040620715623924","article-title":"Hepatitis C virus-associated B-cell non-Hodgkin\u2019s lymphomas: what do we know?","volume":"7","author":"Vannata","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.dld.2018.09.022_bib0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4254\/wjh.v3.i11.278","article-title":"Hepatitis C virus-related B cell subtypes in non Hodgkin\u2019s lymphoma","volume":"3","author":"Pellicelli","year":"2011","journal-title":"World J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0255","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.29198","article-title":"Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas","volume":"66","author":"Merli","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0260","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0265","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3109\/10428194.2013.879712","article-title":"Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey","volume":"55","author":"Marignani","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2018.09.022_bib0270","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.2013.094318","article-title":"Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi","volume":"99","author":"Merli","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2018.09.022_bib0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.V100.1.17","article-title":"Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation","volume":"100","author":"Angelucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0280","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors","volume":"114","author":"Re","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0285","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.dld.2018.09.022_bib0290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.dld.2018.09.022_bib0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.dld.2010.05.010","article-title":"HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin\u2019s lymphoma treated with rituximab-containing regimens","volume":"43","author":"Marignani","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0300","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/PAS.0000000000000345","article-title":"Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of fatal cases","volume":"39","author":"Evans","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2018.09.022_bib0305","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/17474086.2017.1349607","article-title":"From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?","volume":"10","author":"Visentini","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.dld.2018.09.022_bib0310","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2018.09.022_bib0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"Tarella","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.dld.2018.09.022_bib0320","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0325","unstructured":"NCCN guidelines, version 1, 2014: non-Hodgkin\u2019s lymphomas (2017 update). Available at: http:\/\/www.nccn.org\/professionals\/default.aspx."},{"key":"10.1016\/j.dld.2018.09.022_bib0330","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14656566.2017.1288718","article-title":"Antiviral therapies for managing viral hepatitis in lymphoma patients","volume":"18","author":"Merli","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dld.2018.09.022_bib0335","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbmt.2015.07.033","article-title":"Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation task force recommendations","volume":"21","author":"Torres","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"year":"2013","series-title":"ESMO handbook on cancer treatment in special clinical situations","key":"10.1016\/j.dld.2018.09.022_bib0340"},{"key":"10.1016\/j.dld.2018.09.022_bib0345","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/TP.0000000000001708","article-title":"International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0350","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dld.2016.12.027","article-title":"Common issues in the management of patients in the waiting list and after liver transplantation","volume":"49","author":"Burra","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0355","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1053\/jlts.2003.50248","article-title":"The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients","volume":"9","author":"Gane","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2018.09.022_bib0360","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jhep.2012.12.014","article-title":"Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment","volume":"58","author":"Berenguer","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0365","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0370","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/TP.0000000000001704","article-title":"International liver transplantation society consensus statement on hepatitis C management in liver transplant recipients","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0375","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0380","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2018.09.022_bib0385","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0390","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0395","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0400","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0405","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/apt.14017","article-title":"Systematic review: interferon-free regimens for patients with HCV-related child C cirrhosis","volume":"45","author":"Guarino","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2018.09.022_bib0410","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0000000000001611","article-title":"Before or after transplantation? A review of the cost effectiveness of treating waitlisted patients with Hepatitis C","volume":"101","author":"Tapper","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0415","first-page":"461","article-title":"EASL guidelines on hepatitis C","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0420","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0425","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2017.03.006","article-title":"ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients","volume":"67","author":"Belli","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0430","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1097\/TP.0000000000001926","article-title":"Direct-acting antiviral therapy and improvement in graft survival of hepatitis C liver transplant recipients","volume":"101","author":"Cholankeril","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0435","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/liv.12133","article-title":"Calcineurin inhibitors in liver transplantation \u2014 still champions or threatened by serious competitors?","volume":"33","author":"Beckebaum","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.09.022_bib0440","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13255","article-title":"Current challenges and future directions for liver transplantation","volume":"37","author":"Toniutto","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.09.022_bib0445","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2015.09.002","article-title":"Pros and cons: usage of organs from donors infected with hepatitis C virus \u2014 revision in the direct-acting antiviral era","volume":"64","author":"Coilly","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0450","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.296.15.1843","article-title":"Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients","volume":"296","author":"Gasink","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2018.09.022_bib0455","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1053-2498(98)00053-9","article-title":"Hepatitis C virus infection and lung transplantation: a survey of practices","volume":"18","author":"Cotler","year":"1999","journal-title":"J Hear Lung Transplant"},{"key":"10.1016\/j.dld.2018.09.022_bib0460","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/gast.2000.7951","article-title":"Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival","volume":"119","author":"Lunel","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2018.09.022_bib0465","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1053-2498(01)00255-8","article-title":"HBV and HCV infections in heart transplant recipients","volume":"20","author":"Fagiuoli","year":"2001","journal-title":"J Hear Lung Transpl"},{"key":"10.1016\/j.dld.2018.09.022_bib0470","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-0012.1998.tb01061.x","article-title":"Hepatitis C status of heart transplant recipients","volume":"12","author":"Fagiuoli","year":"1998","journal-title":"Clin Transpl"},{"key":"10.1016\/j.dld.2018.09.022_bib0475","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/00007890-199712270-00026","article-title":"Serologic responses to hepatitis C virus in solid organ transplant recipients","volume":"64","author":"Preiksaitis","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0480","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.cld.2006.08.025","article-title":"Hepatitis C in transplant recipients of solid organs, other than liver","volume":"10","author":"Wells","year":"2006","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0485","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e3181e17032","article-title":"Influence of preexisting hepatitis C virus antibody positivity in simultaneous pancreas-kidney transplant recipients","volume":"90","author":"Miguel","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0490","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.TP.0000055834.67634.74","article-title":"Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients","volume":"75","author":"Fagiuoli","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0495","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.transproceed.2012.03.024","article-title":"The outcome of heart transplantation in hepatitis C-positive recipients","volume":"44","author":"Lin","year":"2012","journal-title":"Transpl Proc"},{"key":"10.1016\/j.dld.2018.09.022_bib0500","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.transproceed.2009.12.061","article-title":"The effect of recipient hepatitis C virus infection on outcomes following heart transplantation","volume":"42","author":"Shafii","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2018.09.022_bib0505","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.amjcard.2016.04.023","article-title":"Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for Organ Sharing Database)","volume":"118","author":"Kumar","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dld.2018.09.022_bib0510","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.healun.2011.06.003","article-title":"Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity","volume":"30","author":"Lee","year":"2011","journal-title":"J Hear Lung Transplant"},{"key":"10.1016\/j.dld.2018.09.022_bib0515","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/TP.0b013e3182193cd3","article-title":"Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients","volume":"91","author":"Fong","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2018.09.022_bib0520","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/ajt.13796","article-title":"Survival following lung transplantation in not impacted by hepatitis C infection","volume":"16","author":"Doucette","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.dld.2018.09.022_bib0525","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.healun.2007.01.037","article-title":"Outcomes after lung transplantation in patients with chronic hepatitis C virus infection","volume":"26","author":"Sahi","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.dld.2018.09.022_bib0530","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.13693","article-title":"Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry","volume":"44","author":"Koenig","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2018.09.022_bib0535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1034\/j.1399-0012.2002.01116.x","article-title":"Impact of hepatitis C virus status in pancreas transplantation: a case controlled study","volume":"16","author":"Honaker","year":"2002","journal-title":"Clin Transpl"},{"key":"10.1016\/j.dld.2018.09.022_bib0540","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.29572","article-title":"The rise of the opioid epidemic and hepatitis C positive organs: a new era in liver transplantation","volume":"67","author":"Gonzalez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0545","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0550","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cardfail.2017.08.448","article-title":"Rational heart transplant from hepatitis C donor: new antiviral weapons conquer the trojan","volume":"23","author":"Gottlieb","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.dld.2018.09.022_bib0555","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.13367","article-title":"Epidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in France","volume":"37","author":"Isnard Bagnis","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2018.09.022_bib0560","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.transproceed.2008.03.031","article-title":"Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data","volume":"40","author":"Kliem","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2018.09.022_bib0565","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2215\/CJN.02930806","article-title":"The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment","volume":"2","author":"Terrault","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.dld.2018.09.022_bib0570","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1525-139X.2007.00311.x","article-title":"Hepatitis C virus infection and the dialysis patient","volume":"20","author":"Fabrizi","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.dld.2018.09.022_bib0575","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2018.09.022_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2975","article-title":"Hepatitis C cure with antiviral therapy-benefits beyond the liver","volume":"21","author":"Soriano","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2018.09.022_bib0585","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2018.09.022_bib0590","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1681\/ASN.2017060673","article-title":"Transplantation of kidneys from HCV-positive donors: how to best use a scarce resource","volume":"28","author":"Roth","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.dld.2018.09.022_bib0595","first-page":"420","article-title":"Arthritis in patients with chronic hepatitis C virus infection","volume":"26","author":"Rivera","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0600","first-page":"370","article-title":"Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis","volume":"26","author":"Taglione","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0605","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dld.2011.07.016","article-title":"Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy","volume":"44","author":"Coppola","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0610","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.rdc.2016.09.011","article-title":"Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents","volume":"43","author":"Cacoub","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.dld.2018.09.022_bib0615","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.dld.2014.04.014","article-title":"Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems","volume":"46","author":"Di Domenicantonio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2018.09.022_bib0620","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2013.07.014","article-title":"Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease","volume":"11","author":"Allen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.09.022_bib0625","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.dld.2018.09.022_bib0630","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jinf.2017.02.009","article-title":"Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease","volume":"74","author":"Mazzola","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.dld.2018.09.022_bib0635","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00007890-199110000-00013","article-title":"Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis. A retrospective study in 80 patients with follow-up of 60 months","volume":"52","author":"Cadranel","year":"1991","journal-title":"Transplantation"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:55:03Z","timestamp":1761083703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865818309927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1590865818309927"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.022","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AISF position paper on HCV in immunocompromised patients","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}